Menu

ISTOCK, ZORAZHUANG

Novartis and Sanofi Stockpile Meds in Preparation for Brexit

If the UK leaves the EU in March without a deal, transport of insulin and other essential drugs could be delayed.

Aug 3, 2018
Ashley Yeager

Novartis, Sanofi, and other drug companies are preparing for Brexit by stockpiling their medicines. Sanofi, the world’s lead supplier of insulin, will soon have a 14-week supply of its drugs stored in the UK, The Wall Street Journal reported on Wednesday (August 1).

“Sanofi is confident that its contingency plans will ensure that people in the UK can access the treatments they need after the UK leaves the European Union,” Hugo Fry, managing director of the company’s UK arm, tells BBC News.

Drug makers are preparing for what’s called a no-deal Brexit, where the UK will no longer be subject to EU law but will not have finalized future trade deals with European countries, meaning that there may be delays or barriers to cross-border transactions for drugs and other goods. According to Reuters, over 2,600 drugs go through at least one manufacturing stage in Britain, and each month 45 million patient packs move from the UK to other European countries, while 37 million move from those countries to the UK. Without trade deals, supply lines could get backed up.

The European Medicines Agency, an organization that performs a similar role to the US Food and Drug Administration and that is slated to relocate from London to Amsterdam following the Brexit referendum result, also has “serious concerns” about patient access to more than 100 drugs manufactured exclusively in the UK, Reuters reports. 

Because so many medicinal products move between continental Europe and the UK, drug makers have repeatedly called for the pharma sector to stay in the European regulatory system. But it is still not clear if this can be negotiated. As a result, the two largest UK-based drug companies—AstraZeneca and GlaxoSmithKline—are also implementing contingency plans for a no-deal Brexit.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.